Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial)

A E Rodríguez; M Rodríguez Alemparte; C F Vigo; C Fernández Pereira; C Llauradó; D Vetcher; A Pocovi; J Ambrose

doi:10.1136/hrt.2004.050617

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BCS

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Browse by collection

Authors

About

Podcasts
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via BCS

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Interventional cardiology and surgery

Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Rodríguez AE, Rodríguez Alemparte M, Vigo CF, et al

Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial)

Heart 2005;91:1433-1437.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password